Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pegylated interferon

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    179 result(s) found for: Pegylated interferon. Displaying page 2 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2009-012579-90 Sponsor Protocol Number: 1220.40 Start Date*: 2009-08-04
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and...
    Medical condition: chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002724 Anti-HCV positive LLT
    9.1 10019183 HCV LLT
    9.1 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018870-19 Sponsor Protocol Number: 1708/17.09.09 Start Date*: 2009-09-17
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: randomized study for hcv recurrence treatment in liver transplant patients with ribavirin pre-treatment for 8 weeks follwed by stadard therapy (48 weeks) with interferon pegylated and ribavirin vs ...
    Medical condition: liver tranplanted patients with diagnosis of Hepatitis C recurrence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019805 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007147-28 Sponsor Protocol Number: CLI-107-07 Start Date*: 2008-02-29
    Sponsor Name:CYTHERIS
    Full Title: A PHASE I/IIa DOSE ESCALATION STUDY OF REPEATED ADMINISTRATION OF “CYT107” (glyco-r-hIL-7) ADD ON TREATMENT IN GENOTYPE 1 or 4 HCV INFECTED PATIENTS RESISTANT TO PEGYLATED INTERFERON-ALPHA AND RIB...
    Medical condition: Hepatitis C, genotypes 1 and 4
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005385-12 Sponsor Protocol Number: GI-5005-02 Start Date*: 2008-04-11
    Sponsor Name:GlobeImmune, Inc.
    Full Title: A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant Saccharomyces cerevisiae Expressing a Hepatitis ...
    Medical condition: The genotype 1 Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057212 Hepatitis viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004717-25 Sponsor Protocol Number: Low-PV Start Date*: 2016-07-08
    Sponsor Name:FONDAZIONE PER LA RICERCA OSPEDALE MAGGIORE DI BERGAMO - FROM
    Full Title: The benefit/risk profile of pegylated proline-Interferon alpha-2b (AOP2014) added to the best available strategy based on phlebotomies in low-risk patients with Polycythemia Vera (PV). The Low-PV r...
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004885-14 Sponsor Protocol Number: AI452-017 Start Date*: 2012-11-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combina...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FI (Completed) NL (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002781-21 Sponsor Protocol Number: CO11/9730 Start Date*: 2012-02-02
    Sponsor Name:Leeds Teaching Hospitals
    Full Title: A clinical study to evaluate the biological effects of administering rimantadine in patients with hepatitis C virus (HCV) infection alongside standard combination therapy with pegylated interferon ...
    Medical condition: Hepatitis C Virus infection - genotype 1. Genotype 1 is least responsive to current treatment and is the focus of this study. HCV can cause severe liver damage - this study will only recruit those ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000127-42 Sponsor Protocol Number: NRSily1 Start Date*: 2005-03-03
    Sponsor Name:Medical University of Vienna
    Full Title: Non Responder- STUDY: MULTICENTER STUDY TO EVALUATE THE EFFICACY OF SILYMARIN IN ADDITION TO COMBINATION-THERAPY WITH PEGYLATED INTERFERON ALFA 2A (PEG-IFN ALFA 2A) AND RIBAVIRIN IN PATIENTS WI...
    Medical condition: HCV-patients, who have not responded to a previous therapy with INF or PEG-INF +/- Ribavirin.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004544-30 Sponsor Protocol Number: 1241.37 Start Date*: 2013-04-03
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pe...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Prematurely Ended) NO (Completed) IT (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) DE (Completed) DK (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-018146-38 Sponsor Protocol Number: MFN09/15 Start Date*: 2010-05-28
    Sponsor Name:Swedish Orphan International AB
    Full Title: Multicenter randomized controlled study comparing the efficacy and safety of natural Multi-subtype interferon alpha (Multiferon) in association with ribavirin versus retreatment with pegylated inte...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019744 Hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021716-42 Sponsor Protocol Number: 1220.30 Start Date*: 2011-03-11
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and ...
    Medical condition: genotype 1 chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) BE (Completed) GB (Completed) DE (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003280-22 Sponsor Protocol Number: AI452-032 Start Date*: 2013-08-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment n...
    Medical condition: Chronic Hepatitis C Virus (HCV) Infection (Genotypes 1, 2, 3, 4)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001485-15 Sponsor Protocol Number: MYR204 Start Date*: 2019-09-24
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta
    Medical condition: Chronic Hepatitis Delta
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10019763 Hepatitis delta LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-001918-16 Sponsor Protocol Number: SoraPeg2007 Start Date*: 2007-12-20
    Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Full Title: Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study SoraPeg Trial
    Medical condition: Die Studie ist eine nicht-randomisierte, multizentrische und prospektive Phase II-Studie. Im Rahmen der Studie soll eine kombinierte Behandlung mit Sorafenib und pegyliertem Interferon α2b im Stadi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022568-11 Sponsor Protocol Number: AI452-008 Start Date*: 2011-04-20
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-6500...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001072-22 Sponsor Protocol Number: T51/2015 Start Date*: 2016-01-26
    Sponsor Name:Turku University Hospital
    Full Title: Clinical and virological efficacy of pegylated interferon alpha in the treatment of rhinovirus infection in patients with primary hypogammaglobulinemia: randomized controlled trial
    Medical condition: Rhinovirus infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10039107 Rhinovirus infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005560-13 Sponsor Protocol Number: Hep-Net-HIDIT-2 Start Date*: 2009-06-12
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The ...
    Medical condition: To compare the virological efficacy (HDV-RNA) and safety of 96 weeks of therapy with pegylated interferon-alfa-2a plus tenovofir to 96 weeks of therapy with pegylated interferon-alfa-2a plus placeb...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004862 10047455 Viral hepatitis B without mention of hepatic coma, with hepatitis delta LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001878-25 Sponsor Protocol Number: IDX-08C-005 Start Date*: 2011-11-17
    Sponsor Name:Idenix Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination with Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Genotyp...
    Medical condition: Genotype 1 Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-005707-18 Sponsor Protocol Number: SKS-0078 Start Date*: 2008-08-07
    Sponsor Name:Department of Infectious Diseases, Aarhus university Hospital, Skejby
    Full Title: Clinical study of cerebral function in chronic hepatitis C virus patients treated with pegylated interferon alpha-2a and ribivirin
    Medical condition: HCV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021628-84 Sponsor Protocol Number: VX-950-C211 Start Date*: 2011-03-29
    Sponsor Name:Tibotec BVBA
    Full Title: A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genot...
    Medical condition: Hepatitis C Virus (HCV)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) SE (Completed) AT (Completed) IE (Completed) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 03 14:37:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA